3 results about "Developmental dysplasia" patented technology

The invention relates to an ultrasonic image processing method and system for infant developmental dysplasia of hip joints, and the method comprises the steps: obtaining an infant hip joint ultrasonic image to be diagnosed, and segmenting the ultrasonic image into independent image frames; performing target detection on the picture frame to obtain a hip joint bounding box, and preliminarily screening a standard image based on the hip joint bounding box; key point detection is carried out on the basis of the hip joint bounding box, and key point coordinates and confidence are obtained; screening the standard image again based on the key points and the confidence thereof; calculating a reference radius for the screened standard image, and further selecting an optimal standard image; and calculating an alpha angle and a beta angle based on the key point position in the optimal standard image. Compared with the prior art, the image meeting the Graf method standard can be quickly screened out from the original ultrasonic image, meanwhile, the target angle is automatically calculated through the standard images, doctors are assisted in evaluating the development state of the hip joint, and the time and workload of the doctors are remarkably saved.

Embodiments of the present disclosure provide a method for treating developmental dysplasia of the hip. The method includes administering a therapeutically effective amount of a pharmaceutical composition to a subject suffering from the developmental dysplasia of the hip. The pharmaceutical composition includes a substance capable of inhibiting expression of Midkine (MDK), and the substance capable of inhibiting the expression of MDK is Midkine inhibitor (IMDK).

Embodiments of the present disclosure provide a method for treating developmental dysplasia of the hip. The method includes administering a therapeutically effective amount of a pharmaceutical composition to a subject suffering from the developmental dysplasia of the hip. The pharmaceutical composition includes a substance capable of inhibiting expression of Midkine (MDK), and the substance capable of inhibiting the expression of MDK is Midkine inhibitor (IMDK).